Aldeyra enrolls first patient in dry eye chamber clinical trial

Aldeyra announced enrollment of the first patient in a Phase 3 dry eye chamber clinical trial designed to enable a potential resubmission of the new drug application, or NDA, of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease.